



US006967208B2

(12) **United States Patent**
Pinto et al.(10) **Patent No.:** **US 6,967,208 B2**
(45) **Date of Patent:** **Nov. 22, 2005**(54) **LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS**(75) Inventors: **Donald J. P. Pinto**, Churchville, PA (US); **Mimi L. Quan**, Yardley, PA (US); **Michael J. Orwat**, New Hope, PA (US); **Yun-Long Li**, Wilmington, DE (US); **Wei Han**, Yardley, PA (US); **Jennifer X. Qiao**, Princeton, NJ (US); **Patrick Y. S. Lam**, Chadds Ford, PA (US); **Stephanie L. Koch**, Newark, DE (US)(73) Assignee: **Bristol-Myers Squibb Pharma Company**, Princeton, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 139 days.

(21) Appl. No.: **10/245,122**(22) Filed: **Sep. 17, 2002**(65) **Prior Publication Data**

US 2003/0191115 A1 Oct. 9, 2003

Related U.S. Application Data

(60) Provisional application No. 60/324,165, filed on Sep. 21, 2001, and provisional application No. 60/402,317, filed on Aug. 9, 2002.

(51) **Int. Cl.**⁷ **C07D 471/16**; A61K 31/437; A61P 7/02(52) **U.S. Cl.** **514/303**; 546/119; 546/120(58) **Field of Search** 514/303; 546/119, 546/120(56) **References Cited****U.S. PATENT DOCUMENTS**

3,340,269 A	9/1967	Blatter	260/294.7
3,365,459 A	1/1968	Blatter	260/296
3,423,414 A	1/1969	Blatter	260/296
5,998,424 A	12/1999	Galemmo et al.	514/269
6,020,357 A	2/2000	Pinto et al.	514/406
6,060,491 A	5/2000	Pruitt et al.	514/355
6,187,797 B1	2/2001	Pruitt et al.	
6,191,159 B1	2/2001	Pinto	514/406
6,271,237 B1	8/2001	Galemmo et al.	514/256
6,339,099 B1	1/2002	Lam et al.	
6,369,227 B1	4/2002	Lam et al.	
6,399,644 B1	6/2002	Wexler et al.	
6,403,620 B1	6/2002	Galemmo, Jr. et al.	
6,407,256 B1	6/2002	Pinto	
6,413,980 B1	7/2002	Fevig et al.	
6,426,346 B1	7/2002	Pruitt et al.	
6,429,205 B1	8/2002	Jacobson et al.	
6,436,985 B2	8/2002	Pinto	
6,500,855 B1	12/2002	Lam et al.	
6,548,512 B1	4/2003	Pinto et al.	
6,548,525 B2	4/2003	Galemmo, Jr. et al.	
6,569,874 B1	5/2003	Pruitt et al.	
6,602,895 B2	8/2003	Galemmo, Jr. et al.	

6,689,770 B2	2/2004	Wexler et al.
6,706,730 B2	3/2004	Pinto
6,716,841 B2	4/2004	Jacobson et al.
6,750,225 B2	6/2004	Pinto et al.
2002/0025963 A1	2/2002	Lam et al.
2003/0018023 A1	1/2003	Pinto et al.
2003/0069237 A1	4/2003	Fevig et al.
2003/0069258 A1	4/2003	Lam et al.
2003/0078255 A1	4/2003	Pinto
2003/0181466 A1	9/2003	Zhou et al.
2003/0212054 A1	11/2003	Quan et al.
2003/0232804 A1	12/2003	Pinto et al.
2004/0038980 A1	2/2004	Lam et al.
2004/0063772 A1	4/2004	Quan et al.
2004/0073029 A1	4/2004	Pruitt et al.

FOREIGN PATENT DOCUMENTS


WO	WO9420460	1/1994
WO	WO9612720	5/1996
WO	WO9828269	7/1998
WO	WO9828282	7/1998
WO	WO9852948	11/1998
WO	WO9857934	12/1998
WO	WO9857937	12/1998
WO	WO9857951	12/1998
WO	WO9932454	7/1999
WO	WO9932477	7/1999
WO	WO9950255	10/1999
WO	WO0039108	7/2000
WO	WO0039131	7/2000
WO	WO0059902	10/2000
WO	WO0105784	1/2001
WO	WO0119798	3/2001
WO	WO0132628	5/2001
WO	WO 02/074765	9/2002
WO	WO2003048158	6/2003
WO	WO2003049681	6/2003
WO	WO2003099276	12/2003
WO	WO2004083174	9/2004
WO	WO20040831747	9/2004

OTHER PUBLICATIONSF. E. Nielsen et al., "Phosphorus Pentoxide in Organic Synthesis-I", *Tetrahedron*, vol. 38, No. 10, pp. 1435-1441, 1982, RN:83325-18-2.

(Continued)

Primary Examiner—Bruck Kifle(74) *Attorney, Agent, or Firm*—David H. Vance; Jing S. Belfield(57) **ABSTRACT**

The present application describes lactam-containing compounds and derivatives thereof of Formula I:

I
or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.


OTHER PUBLICATIONS

Kumar et al., "Ketene dithioacetals. Part II. Reaction of 3-cyano-4-methylthio-2(1H)-pyridones with hydrazine and guanidine: synthesis of novel substituted and fused pyrazolo[4,3-c]pyridone and pyrido[4,3-d]pyrimidine derivatives", *Journal of the Chemical Society, Perkin Trans-*

actions I: Organic and Bio-Organic Chemistry 1978, No. 8, pp. 857-862 (abstract).


Elodi et al., "Optimization of conditions for the catalytic effect of the factor IXa-factor VIII Complex: Probable role of the complex in the amplification of blood coagulation", *Thromb. Res.*, vol. 15, pp. 617-629, 1979.

3




wherein ring M is a heterocycle, Z is a linker, A is a ring, B is a basic or cyclic group, D is a basic moiety, and E is a ring. Compounds specifically described in WO98/28269, WO98/28282, WO99/32454, U.S. Pat. No. 6,020,357, and U.S. Pat. No. 6,271,237 are not considered to be part of the present invention.

WO98/57951 describes Factor Xa inhibitors of the following formula:




wherein ring M can be a variety of heterocycles and rings D-E represent a heterobicyclic group. Compounds specifically described in WO98/57951 are not considered to be part of the present invention.

WO98/57934 and U.S. Pat. No. 6,060,491 describe Factor Xa inhibitors of the following formula:




wherein ring M is a 6-membered heteroaryl, Z is a linker, A is a ring, B is a basic or cyclic group, D is a basic moiety, and E is a ring. Compounds specifically described in WO98/57934 and U.S. Pat. No. 6,060,491 are not considered to be part of the present invention.

WO98/57937 and U.S. Pat. No. 5,998,424 describe Factor Xa inhibitors of the following formula:




wherein ring M is a variety of rings, ring D is an aromatic ring, and R and E are non-basic groups. Compounds specifically described in WO98/57937 and U.S. Pat. No. 5,998,424 are not considered to be part of the present invention.

WO99/50255 and U.S. Pat. No. 6,191,159 describe pyrazoline and triazolone Factor Xa inhibitors of the following formulas:




4

-continued



Compounds specifically described in WO99/50255 and U.S. Pat. No. 6,191,159 are not considered to be part of the present invention.



WO00/59902 describes Factor Xa inhibitors of the following formula:



wherein ring M can be a variety of rings all of which are substituted with Z-A-B, Z is a linker, A is a ring, B is a sulfonyl-containing heterobicyclic, and rings D-E represent a heterobicyclic group or a 6-membered ring. Compounds specifically described in WO00/59902 are not considered to be part of the present invention.


WO01/32628 describes cyano-pyrroles, cyano-imidazoles, cyano-pyrazoles, and cyano-triazoles that are Factor Xa inhibitors. Compounds specifically described in WO01/32628 are not considered to be part of the present invention.

WO01/05784 describes Factor Xa inhibitors of the following formulas:



wherein Z is C or N, G is a mono- or bicyclic ring M, A is a linker, B is a basic or cyclic group. Compounds specifically described in WO01/05784 are not considered to be part of the present invention.


WO00/39108 describes Factor Xa inhibitors of the following formula:



wherein ring M can be a variety of heterocycles and rings D-E represent a heterobicyclic group. Compounds specifically described in WO00/39108 are not considered to be part of the present invention.

5

WO01/19798 describes factor Xa inhibitors of the following formula:



wherein A, D, G, and X can be phenyl or heterocycle. However, none of the presently claimed compounds are exemplified or suggested in WO01/19798.

Activated factor Xa, whose major practical role is the generation of thrombin by the limited proteolysis of prothrombin, holds a central position that links the intrinsic and extrinsic activation mechanisms in the final common pathway of blood coagulation. The generation of thrombin, the final serine protease in the pathway to generate a fibrin clot, from its precursor is amplified by formation of prothrombinase complex (factor Xa, factor V, Ca^{2+} and phospholipid). Since it is calculated that one molecule of factor Xa can generate 138 molecules of thrombin (Elodi, S., Varadi, K.: Optimization of conditions for the catalytic effect of the factor IXa-factor VIII Complex: Probable role of the complex in the amplification of blood coagulation. *Thromb. Res.* 1979, 15, 617-629), inhibition of factor Xa may be more efficient than inactivation of thrombin in interrupting the blood coagulation system.

Therefore, efficacious and specific inhibitors of factor Xa are needed as potentially valuable therapeutic agents for the treatment of thromboembolic disorders. It is thus desirable to discover new factor Xa inhibitors. In addition, it is also desirable to find new compounds with improved pharmacological characteristics compared with known factor Xa inhibitors. For example, it is preferred to find new compounds with improved factor Xa inhibitory activity and selectivity for factor Xa versus other serine proteases (i.e., trypsin). It is also desirable and preferable to find compounds with advantageous and improved characteristics in one or more of the following categories, but are not limited to: (a) pharmaceutical properties (e.g., solubility, permeability, and amenability to sustained release formulations); (b) dosage requirements (e.g., lower dosages and/or once-daily dosing); (c) factors which decrease blood concentration peak-to-trough characteristics (e.g., clearance and/or volume of distribution); (d) factors that increase the concentration of active drug at the receptor (e.g., protein binding, volume of distribution); (e) factors that decrease the liability for clinical drug-drug interactions (e.g., cytochrome P450 enzyme inhibition or induction); (f) factors that decrease the potential for adverse side-effects (e.g., pharmacological selectivity beyond serine proteases, potential chemical or metabolic reactivity, and limited CNS penetration); and, (g) factors that improve manufacturing costs or feasibility (e.g., difficulty of synthesis, number of chiral centers, chemical stability, and ease of handling).

SUMMARY OF THE INVENTION

Accordingly, the present invention provides novel lactam-containing compounds and derivatives thereof that are useful as factor Xa inhibitors or pharmaceutically acceptable salts or prodrugs thereof.

The present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.

The present invention provides a method for treating thromboembolic disorders comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present

6


The present invention provides a novel method of treating a patient in need of thromboembolic disorder treatment, comprising: administering a compound of the present invention or a pharmaceutically acceptable salt form thereof in an amount effective to treat a thromboembolic disorder.

The present invention provides a novel method, comprising: administering a compound of the present invention or a pharmaceutically acceptable salt form thereof in an amount effective to treat a thromboembolic disorder.

The present invention provides novel lactam-containing compounds and derivatives thereof for use in therapy.

The present invention provides the use of novel lactam-containing compounds for the manufacture of a medicament for the treatment of a thromboembolic disorder.


These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that lactam-containing compounds of Formula I:



wherein P_4 , P, M, and M_4 are defined below, or pharmaceutically acceptable salt or prodrug forms thereof, are effective factor Xa inhibitors.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[1] In an embodiment, the present invention provides a novel compound of Formula I:



or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;

M is a 3-10 membered carbocycle or a 4-10 membered heterocycle, consisting of: carbon atoms and 1-3 heteroatoms selected from O, $S(O)_p$, N, and NZ^2 ;


ring M is substituted with 0-3 R^{1a} and 0-2 carbonyl groups, and there are 0-3 ring double bonds;

P is fused onto ring M and is a 5, 6, or 7 membered carbocycle or a 5, 6, or 7 membered heterocycle, consisting of: carbon atoms and 1-3 heteroatoms selected from O, $S(O)_p$, and N;


ring P is substituted with 0-3 R^{1a} and 0-2 carbonyl groups, and there are 0-3 ring double bonds;

alternatively, ring P is absent and P_4 is directly attached to ring M, provided that when ring P is absent, P_4 and M_4 are attached to the 1,2, 1,3, or 1,4 positions of ring M;

one of P_4 and M_4 is $-Z-A-B$ and the other $-G_1-G$; G is a group of Formula IIa or IIb:



IIa



IIb

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.